ClinicalTrials.gg
CompletedNCT02667639Updated Dec 28, 2021Results posted

Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects

A Phase 1 interventional study of RPH-104 and Sodium chloride Sterile Injection 0.9% w/v in Healthy, sponsored by R-Pharm. Completed at 1 site in Turkey. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-28.

Sponsored by R-Pharm · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

The purpose of this first in human study is to evaluate the safety and tolerability of RPH-104 in humans.

Read the detailed description

RPH-104 is a macromolecular compound with a molecular weight of 152.715 kilodalton (Data on file) and is capable of binding human interleukin-1 beta (IL-1β). It has also been shown in vitro to be a highly potent inhibitor of IL-1β signalling pathway, with low picomolar inhibitor activity. In this First in Human study, RPH-104 will be evaluated primarily for its safety and tolerability. In a phase I study conducted with health volunteers, a similar monoclonal antibody, canakinumab, was investigated in terms of pharmacokinetics and pharmacodynamics besides efficacy and safety. Similarly, this aimed to investigate effects of RPH-104 on selected pharmacodynamic parameters, including Anti-Drug Antibodies (ADA) along with obtaining first human data on pharmacokinetics of RPH-104 in humans will be investigated in the same study.

02

Conditions studied

  • Healthy

Keywords

  • safety
  • tolerability
  • RPH-104
  • RPH104
  • Anti-IL1 beta
  • Anti-IL1
03

In context

Lead sponsor

R-Pharm is the lead sponsor of 58 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy subjects.
  • Male or female subjects between 18 and 35 years old (inclusive).
  • Subject who has normal body weight as determined by a (BMI) of between 18 kg/m² and 30 kg/m² (inclusive) and within a body weight of ≥50kg and ≤120kg.

Exclusion criteria

Exclusion Criteria:

  • Subject who has a history or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrinological, dermatological, neurological, psychiatric, and hematological or immunological disorder(s), and/or any condition that could constitute a potential safety risk factor or could alter the absorption, distribution, metabolism or elimination of the study drugs.
  • Subject who has positive immunoglobulin-M (IgM) antibodies against Epstein-Barr virus (EBV)-viral capsid antigen (VCA) (IgM-anti-EBV-VCA) and Cytomegalovirus (CMV).
  • Subject who has a positive Quantiferon TB-Gold (TB) test
  • Subject who is positive to -1/2 antibody (HIV-1/2Ab).
  • Subject who has serum hepatitis, or is a carrier of the surface antigen (HBsAg), or is virus antibody (HCV-Ab) positive.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Active comparator
    Treatment

    A single dose of RPH-104 (4, 20, 40, 80 or 160 mg) will be administered subcutaneously.

    Biological: RPH-104

  • Placebo comparator
    Placebo

    A single 0.9% sodium chloride injection will be administered subcutaneously.

    Other: Sodium chloride Sterile Injection 0.9% w/v

Interventions

  • BiologicalRPH-104

    Anti-IL-1 Mab

  • OtherSodium chloride Sterile Injection 0.9% w/v

    Sterile saline solution

06

What researchers measure

Primary outcomes

  1. Adverse Events

    Number of participants with study drug related adverse events

    Time frame: Until 60 days after administration

  2. Serious Adverse Events

    Number of Participants with Study Drug Related Serious Adverse Events

    Time frame: Until 60 days after administration

  3. Respiratory Rate

    Percentage of participants with abnormal respiratory rate. The normal respiration rate for an adult at rest is 12 to 20 breaths per minute.

    Time frame: Until 30 days after administration

  4. Blood Pressure

    Percentage of participants with abnormal blood pressure. An optimal blood pressure level is a reading under 120/80 mmHg

    Time frame: Until 30 days after administration

  5. Oxygen Saturation

    Percentage of participants with abnormal oxygen saturation. Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.

    Time frame: Until 30 days after administration

  6. Body Temperature

    Percentage of participants with abnormal body temperature. Among adults, the average body temperature ranges from 97°F (36.1°C) to 99°F (37.2°C).

    Time frame: Until 30 days after administration

  7. Clinical Laboratory Tests

    Percentage of participants with abnormal clinical laboratory tests. Normal laboratory ranges of the central laboratory were used.

    Time frame: Until 30 days after administration

Secondary outcomes

  1. RPH-104 - Area Under the Curve (AUC)

    Mean AUC 0-t (area under the concentration- time curve from time zero to day 30)

    Time frame: Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30

  2. RPH-104 - Time to Maximum Concentration (Tmax)

    Median Tmax. Definition of Tmax is time at which Cmax occurs.

    Time frame: Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30

  3. RPH-104 - Elimination Half-life (t1/2)

    Mean t½. Definition of t½ is terminal elimination half-life.

    Time frame: Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30

  4. RPH-104 - Maximum Plasma Concentration (Cmax)

    Mean Cmax. Highest concentration determined in the measuring interval.

    Time frame: Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30

07

Results

Posted Oct 4, 2019

Participant flow

Participant flow — Overall Study
MilestoneTreatmentPlacebo
Started2510
Completed2510
Not completed00

Outcome measures

PrimaryAdverse Events

Number of participants with study drug related adverse events

Time frame:
Until 60 days after administration
Reported as:
Number · participants
Adverse Events
participantsTreatmentPlacebo
Adverse Events00
PrimarySerious Adverse Events

Number of Participants with Study Drug Related Serious Adverse Events

Time frame:
Until 60 days after administration
Reported as:
Count of participants · Participants
Serious Adverse Events
ParticipantsTreatmentPlacebo
Serious Adverse Events00
PrimaryRespiratory Rate

Percentage of participants with abnormal respiratory rate. The normal respiration rate for an adult at rest is 12 to 20 breaths per minute.

Time frame:
Until 30 days after administration
Reported as:
Number · percentage of participants
Respiratory Rate
percentage of participantsTreatmentPlacebo
Respiratory Rate00
PrimaryBlood Pressure

Percentage of participants with abnormal blood pressure. An optimal blood pressure level is a reading under 120/80 mmHg

Time frame:
Until 30 days after administration
Reported as:
Number · percentage of participants
Blood Pressure
percentage of participantsTreatmentPlacebo
Blood Pressure00
PrimaryOxygen Saturation

Percentage of participants with abnormal oxygen saturation. Normal pulse oximeter readings usually range from 95 to 100 percent. Values under 90 percent are considered low.

Time frame:
Until 30 days after administration
Reported as:
Number · percentage of participants
Oxygen Saturation
percentage of participantsTreatmentPlacebo
Oxygen Saturation00
PrimaryBody Temperature

Percentage of participants with abnormal body temperature. Among adults, the average body temperature ranges from 97°F (36.1°C) to 99°F (37.2°C).

Time frame:
Until 30 days after administration
Reported as:
Number · percentage of participants
Body Temperature
percentage of participantsTreatmentPlacebo
Body Temperature00
PrimaryClinical Laboratory Tests

Percentage of participants with abnormal clinical laboratory tests. Normal laboratory ranges of the central laboratory were used.

Time frame:
Until 30 days after administration
Reported as:
Number · percentage of participants
Clinical Laboratory Tests
percentage of participantsTreatmentPlacebo
Clinical Laboratory Tests00
SecondaryRPH-104 - Area Under the Curve (AUC)

Mean AUC 0-t (area under the concentration- time curve from time zero to day 30)

Time frame:
Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30
Reported as:
Mean · hr*ng/mL
RPH-104 - Area Under the Curve (AUC)
hr*ng/mLTreatmentPlacebo
4 mg74500 ± 247000 ± 0
20 mg430000 ± 957000 ± 0
40 mg661000 ± 1580000 ± 0
80 mg1610000 ± 3170000 ± 0
160 mg3390000 ± 14500000 ± 0
SecondaryRPH-104 - Time to Maximum Concentration (Tmax)

Median Tmax. Definition of Tmax is time at which Cmax occurs.

Time frame:
Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30
Reported as:
Median · hr
RPH-104 - Time to Maximum Concentration (Tmax)
hrTreatmentPlacebo
4 mg96 (94.4 to 192)0 (0 to 0)
20 mg96 (48 to 96.2)0 (0 to 0)
40 mg120 (96.0 to 192)0 (0 to 0)
80 mg96 (72.0 to 120)0 (0 to 0)
160 mg120 (72.0 to 120)0 (0 to 0)
SecondaryRPH-104 - Elimination Half-life (t1/2)

Mean t½. Definition of t½ is terminal elimination half-life.

Time frame:
Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30
Reported as:
Mean · hr
RPH-104 - Elimination Half-life (t1/2)
hrTreatmentPlacebo
4 mg245 ± 9.500 ± 0
20 mg249 ± 6.080 ± 0
40 mg255 ± 43.10 ± 0
80 mg235 ± 22.80 ± 0
160 mg243 ± 40.40 ± 0
SecondaryRPH-104 - Maximum Plasma Concentration (Cmax)

Mean Cmax. Highest concentration determined in the measuring interval.

Time frame:
Day 1, Day 2, Day3, Day 4, Day 5, Day 6, Day 9, Day 12, Day 15, Day 20, Day 25, Day 30
Reported as:
Mean · ng/mL
RPH-104 - Maximum Plasma Concentration (Cmax)
ng/mLTreatmentPlacebo
4 mg198 ± 89.10 ± 0
20 mg1280 ± 4020 ± 0
40 mg1650 ± 2570 ± 0
80 mg5120 ± 14100 ± 0
160 mg10300 ± 44700 ± 0

Adverse events

Collected over 60 days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment0/25 (0%)0/25 (0%)22/25 (88%)
Placebo0/10 (0%)0/10 (0%)7/10 (70%)
Most frequent other events
Showing 10 of 13
Most frequent other events
EventTreatmentPlacebo
Nervous system disordersNervous system disorders13/254/10
Gastrointestinal disordersGastrointestinal disorders8/254/10
Infections and infestationsInfections and infestations6/253/10
General disorders and administration site conditionsGeneral disorders3/252/10
Musculoskeletal and connective tissue disordersMusculoskeletal and connective tissue disorders2/252/10
Ear and labyrinth disordersEar and labyrinth disorders1/251/10
Cardiac disordersCardiac disorders0/251/10
Reproductive system and breast disordersReproductive system and breast disorders0/251/10
Skin and subcutaneous tissue disordersSkin and subcutaneous tissue disorders2/250/10
InvestigationsInvestigations2/250/10

Baseline characteristics

All subjects receiving the study medication will be included into the safety evaluation. Subjects who completed the study according to the protocol (per protocol population) will be included into the statistical evaluation. Subject data of drop-out volunteers or volunteers who were not eligible for the study will not be included into statistics.

Age, Customized
Age, Customized(participants)TreatmentPlaceboTotal
18-35251010
Sex: Female, Male
Sex: Female, Male(Participants)TreatmentPlaceboTotal
Female213
Male23932
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)TreatmentPlaceboTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)TreatmentPlaceboTotal
Turkey251035
08

Study locations

1 site
  • ARGEFAR
    Izmir, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2016, a primary completion of Jun 2017 and a completion of Jun 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2019, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2016
First posted
Jan 29, 2016
Start
Jan 2016
Primary completionActual
Jun 2017
CompletionActual
Jun 2017
Results first posted
Oct 4, 2019
Last update
Dec 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02667639
Lead sponsor
R-Pharm
Collaborators
MonitorCRO
Responsible party
Sponsor
First posted
Jan 29, 2016
Start date
Jan 2016
Primary completion
Jun 2017
Completion
Jun 2017
Results posted
Oct 4, 2019
Last update
Dec 28, 2021

Study contacts

Sibel Goksel, MD, PhD
principal investigator · ARGEFAR

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Goflikicept

Start the discussion